# Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

> **NCT04265872** · EARLY_PHASE1 · RECRUITING · sponsor: **Baylor Research Institute** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis

## Key facts

- **NCT ID:** NCT04265872
- **Lead sponsor:** Baylor Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-10-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265872, "Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04265872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*